Mutya has made over 2 trades of the Menlo Therapeutics stock since 2019, according to the Form 4 filled with the SEC. Most recently she sold 639 units of MNLO stock worth $1,502 on 1 July 2019.
The largest trade she's ever made was selling 2,519 units of Menlo Therapeutics stock on 1 April 2019 worth over $9,446. On average, Mutya trades about 175 units every 5 days since 2018. As of 1 July 2019 she still owns at least 51,969 units of Menlo Therapeutics stock.
You can see the complete history of Ms. Harsch stock trades at the bottom of the page.
Mutya Fonte Harsch serves as Chief Legal Officer, General Counsel of the Company. From January 2019 until the Closing Date, Ms. Harsch served as the General Counsel and Chief Legal Officer of Foamix. She previously served as Foamix’s General Counsel and Senior Vice President of Legal Affairs from January 2018 to January 2019. Ms. Harsch has over 19 years of legal experience, previously holding positions as Special Counsel, Mergers & Acquisitions at Cooley LLP from 2015 to 2017 and as a corporate lawyer at Davis Polk & Wardwell from 2005 to 2015. Ms. Harsch received her J.D. and B.A. from the University of California at Berkeley.
Mutya Harsch is 45, she's been the Chief Legal Officer and General Counsel of Menlo Therapeutics since 2020. There are 9 older and no younger executives at Menlo Therapeutics. The oldest executive at Menlo Therapeutics, Inc. is Rex Bright, 79, who is the Director.
Mutya's mailing address filed with the SEC is Rehovot, Israel.
Over the last 7 years, insiders at Menlo Therapeutics have traded over $3,825,000 worth of Menlo Therapeutics stock and bought 3,655,938 units worth $21,205,011 . The most active insiders traders include Advisors Llcperceptive Life..., Llc Fmr, and Albert Cha. On average, Menlo Therapeutics executives and independent directors trade stock every 85 days with the average trade being worth of $572,944. The most recent stock trade was executed by Sharon Barbari on 20 August 2020, trading 75,000 units of MNLO stock currently worth $111,000.
Menlo Therapeutics Inc. operates as biopharmaceutical company which is focused on the development and commercialization of serlopitant for the treatment of pruritus, or itch, associated with dermatologic conditions such as atopic dermatitis, psoriasis and prurigo nodularis. The company was founded by Ed F. Schnipper in October, 2011 and is headquartered in Redwood City, CA.
Menlo Therapeutics executives and other stock owners filed with the SEC include: